PURPOSE: We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (CSRT) to patients with high-risk medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumors, and we report the outcome in the subset with metastatic (M+) MB. PATIENTS AND METHODS: After surgery, patients received 36 Gy CSRT with boosts to sites of disease. During radiation, patients received 15 to 30 doses of carboplatin (30-45 mg/m(2)/dose), along with vincristine (VCR) once per week for 6 weeks. Patients on regimen A received 6 months of maintenance chemotherapy (MC) with cyclophosphamide and VCR. Once the recommended phase II dose (RP2D) of carboplatin was determined, cisplatin was added to the MC (regimen B). RESULTS: In all, 161 eligible patients (median age, 8.7 years; range, 3.1 to 21.6 years) were enrolled. Myelosuppression was dose limiting and 35 mg/m(2)/dose × 30 was determined to be the RP2D of carboplatin. Twenty-nine (36%) of 81 patients with M+ MB had diffuse anaplasia. Four patients were taken off study within 11 months of completing radiotherapy for presumed metastatic progression and are long-term survivors following palliative chemotherapy. Excluding these four patients, 5-year overall survival ± SE and progression-free survival ± SE for M+ patients treated at the RP2D on regimen A was 82% ± 9% and 71% ± 11% versus 68% ± 10% and 59% ± 10% on regimen B (P = .36). There was no difference in survival by M stage. Anaplasia was a negative predictor of outcome. CONCLUSION: The use of carboplatin as a radiosensitizer is a promising strategy for patients with M+ MB. Early progression should be confirmed by biopsy.
PURPOSE: We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (CSRT) to patients with high-risk medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumors, and we report the outcome in the subset with metastatic (M+) MB. PATIENTS AND METHODS: After surgery, patients received 36 Gy CSRT with boosts to sites of disease. During radiation, patients received 15 to 30 doses of carboplatin (30-45 mg/m(2)/dose), along with vincristine (VCR) once per week for 6 weeks. Patients on regimen A received 6 months of maintenance chemotherapy (MC) with cyclophosphamide and VCR. Once the recommended phase II dose (RP2D) of carboplatin was determined, cisplatin was added to the MC (regimen B). RESULTS: In all, 161 eligible patients (median age, 8.7 years; range, 3.1 to 21.6 years) were enrolled. Myelosuppression was dose limiting and 35 mg/m(2)/dose × 30 was determined to be the RP2D of carboplatin. Twenty-nine (36%) of 81 patients with M+ MB had diffuse anaplasia. Four patients were taken off study within 11 months of completing radiotherapy for presumed metastatic progression and are long-term survivors following palliative chemotherapy. Excluding these four patients, 5-year overall survival ± SE and progression-free survival ± SE for M+ patients treated at the RP2D on regimen A was 82% ± 9% and 71% ± 11% versus 68% ± 10% and 59% ± 10% on regimen B (P = .36). There was no difference in survival by M stage. Anaplasia was a negative predictor of outcome. CONCLUSION: The use of carboplatin as a radiosensitizer is a promising strategy for patients with M+ MB. Early progression should be confirmed by biopsy.
Authors: H G Brown; J L Kepner; E J Perlman; H S Friedman; D R Strother; P K Duffner; L E Kun; P T Goldthwaite; P C Burger Journal: J Neuropathol Exp Neurol Date: 2000-10 Impact factor: 3.685
Authors: Charles G Eberhart; James L Kepner; Patricia T Goldthwaite; Larry E Kun; Patricia K Duffner; Henry S Friedman; Douglas R Strother; Peter C Burger Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin Journal: Cancer Res Date: 1982-06 Impact factor: 12.701
Authors: R D Kortmann; J Kühl; B Timmermann; U Mittler; C Urban; V Budach; E Richter; N Willich; M Flentje; F Berthold; I Slavc; J Wolff; C Meisner; O Wiestler; N Sörensen; M Warmuth-Metz; M Bamberg Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: R J Packer; L N Sutton; R Elterman; B Lange; J Goldwein; H S Nicholson; L Mulne; J Boyett; G D'Angio; K Wechsler-Jentzsch Journal: J Neurosurg Date: 1994-11 Impact factor: 5.115
Authors: R Mastrangelo; A Lasorella; R Riccardi; C Colosimo; A Iavarone; A Tornesello; S Mastrangelo; G Ausili-Cefaro; C Di Rocco Journal: Med Pediatr Oncol Date: 1995-03
Authors: E Bouffet; J C Gentet; F Doz; P Tron; H Roche; D Plantaz; A Thyss; J L Stephan; C Lasset; C Carrie Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: T de Rojas; M Puertas; F Bautista; I de Prada; M Á López-Pino; B Rivero; C Gonzalez-San Segundo; M Gonzalez-Vicent; A Lassaletta; L Madero; L Moreno Journal: Clin Transl Oncol Date: 2019-04-01 Impact factor: 3.405
Authors: Paul L Moots; Anne O'Neill; Harold Londer; Minesh Mehta; Deborah T Blumenthal; Geoffrey R Barger; Margaret L Grunnet; Stuart Grossman; Mark R Gilbert; David Schiff Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339
Authors: John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289
Authors: Adam J Esbenshade; Mehmet Kocak; Linda Hershon; Pierre Rousseau; Jean-Claude Decarie; Susan Shaw; Peter Burger; Henry S Friedman; Amar Gajjar; Albert Moghrabi Journal: Pediatr Blood Cancer Date: 2016-12-21 Impact factor: 3.167
Authors: Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Stefan Blüml; Ashley S Margol; Richard Sposto; Rebekah J Kennedy; Nathan J Robison; Marzieh Vali; Long T Hung; Sakunthala Muthugounder; Jonathan L Finlay; Anat Erdreich-Epstein; Floyd H Gilles; Alexander R Judkins; Mark D Krieger; Girish Dhall; Marvin D Nelson; Shahab Asgharzadeh Journal: Neuro Oncol Date: 2015-08-08 Impact factor: 12.300